PMID- 32801888
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1179-1322 (Print)
IS  - 1179-1322 (Electronic)
IS  - 1179-1322 (Linking)
VI  - 12
DP  - 2020
TI  - A Review About Pembrolizumab in First-Line Treatment of Advanced NSCLC: Focus on 
      KEYNOTE Studies.
PG  - 6493-6509
LID - 10.2147/CMAR.S257188 [doi]
AB  -  Lung cancer is currently the malignant tumor with the highest incidence and 
      mortality in the world, while non-small cell lung cancer (NSCLC) is the most 
      common pathological type of lung caner. In the past few decades, the only 
      treatment options available for advanced NSCLC patients have been targeted 
      therapy or chemotherapy, but these therapies are inevitably tolerated by tumors. 
       The discovery of immune checkpints that mediate the immune escape of tumor cells 
      have been promoting a series of immune checkpoint inhibitors to be used in cancer 
      treatment and achieved great results. Among them, pembrolizumab is currently the 
      only PD-1 inhibitor approved for first-line treatment of NSCLC, whether it is 
      monotherapy or combination therapy, for creditable performance in KEYNOTE 
      studies. In this review, we systematically integrate the latest series of 
      clinical trial results, pharmacological mechanisms, adverse events (AEs) and 
      predictive biomarkers in the first-line treatment of NSCLC. We hope pembrolizumab 
      could become a better choice for more clinicians and benefit more patients with 
      advanced NSCLC.
CI  - (c) 2020 Qu et al.
FAU - Qu, Jialin
AU  - Qu J
AD  - Department of Medical Oncology, The Affiliated Hospital of Qingdao University, 
      Qingdao University, Qingdao 266003, People's Republic of China.
FAU - Wang, Li
AU  - Wang L
AUID- ORCID: 0000-0001-5691-9946
AD  - Department of Medical Oncology, The Affiliated Hospital of Qingdao University, 
      Qingdao University, Qingdao 266003, People's Republic of China.
FAU - Jiang, Man
AU  - Jiang M
AD  - Department of Medical Oncology, The Affiliated Hospital of Qingdao University, 
      Qingdao University, Qingdao 266003, People's Republic of China.
FAU - Zhao, Deze
AU  - Zhao D
AD  - Department of Medical Oncology, The Affiliated Hospital of Qingdao University, 
      Qingdao University, Qingdao 266003, People's Republic of China.
FAU - Wang, Yuyang
AU  - Wang Y
AD  - Department of Medical Oncology, The Affiliated Hospital of Qingdao University, 
      Qingdao University, Qingdao 266003, People's Republic of China.
FAU - Zhang, Feng
AU  - Zhang F
AD  - Department of Medical Oncology, The Affiliated Hospital of Qingdao University, 
      Qingdao University, Qingdao 266003, People's Republic of China.
FAU - Li, Jing
AU  - Li J
AD  - Department of Medical Oncology, The Affiliated Hospital of Qingdao University, 
      Qingdao University, Qingdao 266003, People's Republic of China.
FAU - Zhang, Xiaochun
AU  - Zhang X
AD  - Department of Medical Oncology, The Affiliated Hospital of Qingdao University, 
      Qingdao University, Qingdao 266003, People's Republic of China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200728
PL  - New Zealand
TA  - Cancer Manag Res
JT  - Cancer management and research
JID - 101512700
PMC - PMC7395702
OTO - NOTNLM
OT  - KEYNOTE studies
OT  - NSCLC
OT  - PD-1/PD-L1
OT  - first-line treatment
OT  - non-small cell lung cancer
OT  - pembrolizumab
COIS- The authors report no conflicts of interest in this work.
EDAT- 2020/08/18 06:00
MHDA- 2020/08/18 06:01
PMCR- 2020/07/28
CRDT- 2020/08/18 06:00
PHST- 2020/04/09 00:00 [received]
PHST- 2020/06/24 00:00 [accepted]
PHST- 2020/08/18 06:00 [entrez]
PHST- 2020/08/18 06:00 [pubmed]
PHST- 2020/08/18 06:01 [medline]
PHST- 2020/07/28 00:00 [pmc-release]
AID - 257188 [pii]
AID - 10.2147/CMAR.S257188 [doi]
PST - epublish
SO  - Cancer Manag Res. 2020 Jul 28;12:6493-6509. doi: 10.2147/CMAR.S257188. 
      eCollection 2020.